Suppression of hyaluronan synthesis alleviates inflammatory responses in murine arthritis and in human rheumatoid synovial fibroblasts

Arthritis Rheum. 2013 May;65(5):1160-70. doi: 10.1002/art.37861.

Abstract

Objective: To clarify the roles of hyaluronan (HA) in joint inflammation and the process of joint destruction, using 4-methylumbelliferone (4-MU), an inhibitor of HA synthesis, in a mouse model of collagen-induced arthritis (CIA) and in a monolayer culture of fibroblast-like synoviocytes (FLS) derived from patients with rheumatoid arthritis.

Methods: DAB/1J mice were immunized with type II collagen. The effects of 4-MU were evaluated by the physiologic arthritis score, paw swelling, the histologic arthritis score, and expression of matrix metalloproteinase 3 (MMP-3) and MMP-13 in chondrocytes and synovial tissue. In vitro, the effect of 4-MU on messenger RNA and protein expression of MMP-1 and MMP-3 was determined. The effects of 4-MU on HA deposition and on serum/medium concentrations of HA were analyzed using biotinylated HA binding protein staining and an HA binding assay, respectively.

Results: Treatment with 4-MU in mice with CIA dramatically decreased the severity of arthritis (based on the arthritis score), paw thickness, and histopathologic changes. MMP-3 and MMP-13 expression in chondrocytes and synovial cells was significantly inhibited by 4-MU in vivo. Treatment with 4-MU also inhibited MMP-1 and MMP-3 expression in tumor necrosis factor α-stimulated FLS, in a dose-dependent manner. The 4-MU-induced decreases in the serum HA concentration in mice with CIA and in "medium" and "pericellular" HA concentrations in cultured FLS support the contention that the inhibitory mechanism of 4-MU is mediated by HA suppression.

Conclusion: Reduced disease activity induced by 4-MU in mice with CIA revealed HA to be a crucial regulator in the course of arthritis. Therefore, 4-MU is a potential therapeutic agent in arthritis, and its inhibitory mechanism is possibly mediated by suppression of HA synthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / antagonists & inhibitors*
  • Adjuvants, Immunologic / biosynthesis
  • Adjuvants, Immunologic / blood
  • Administration, Oral
  • Animals
  • Antirheumatic Agents / pharmacology
  • Arthritis, Experimental / drug therapy
  • Arthritis, Experimental / metabolism*
  • Arthritis, Experimental / pathology
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / metabolism*
  • Arthritis, Rheumatoid / pathology
  • Cells, Cultured
  • Edema / chemically induced
  • Edema / drug therapy
  • Edema / pathology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Fibroblasts / pathology
  • Gene Knockdown Techniques
  • Hindlimb / drug effects
  • Hindlimb / pathology
  • Humans
  • Hyaluronic Acid / antagonists & inhibitors*
  • Hyaluronic Acid / biosynthesis
  • Hyaluronic Acid / blood
  • Hymecromone / analogs & derivatives
  • Hymecromone / pharmacology
  • Mice
  • Mice, Inbred DBA
  • RNA, Messenger / antagonists & inhibitors
  • RNA, Messenger / metabolism
  • RNA, Small Interfering / genetics
  • Stifle / drug effects
  • Stifle / pathology
  • Synovial Membrane / drug effects
  • Synovial Membrane / metabolism*
  • Synovial Membrane / pathology

Substances

  • Adjuvants, Immunologic
  • Antirheumatic Agents
  • RNA, Messenger
  • RNA, Small Interfering
  • Hymecromone
  • Hyaluronic Acid